# Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults

> **NCT01323959** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 212 (actual)

## Conditions studied

- Acellular Pertussis
- Poliomyelitis
- Diphtheria
- Tetanus

## Interventions

- **BIOLOGICAL:** BoostrixTM Polio

## Key facts

- **NCT ID:** NCT01323959
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-01
- **Primary completion:** 2012-03-01
- **Final completion:** 2012-03-01
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323959, "Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01323959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*